PDT/PDD research
Photosensitizer
Photofrin
The only first-generation cancer treatment approved by the U.S. FDA
포토프린(Photofrin®)
Photofrin contains oligomers of porfimer sodium in porphyrin unit, which is a photosentivie material derivative from hematoporphyrin. Tumors are treated with laser through photodynamic therapy. Photofrin’s wide-area photodynamic treatment is a two-step process; injecting Photofrin intravenously as a first step, and studying the laser light that has a wavelength of 630nm. After 40-72 hours of Photofrin’s intravenous injections, it will be distributed to several tissues, and the organs of tumors, skin, and cortical cortex (including liver, bowels, and spleen) remains longer. Photofrin accumulates three to five times more in tumor cells than in normal cells, enabling tumor-selective treatment through transferring selective light. Photofrin has been clinically validated for early lung cancer, surface esophageal cancer, early cervical cancer and heteroplasia cell cancer since 1989. In addition, it was approved by the U.S. FDA for lung and esophageal cancer in 1995, and is currently used in 30 countries including 200 cancer centers in the U.S, Europe, and Japan as a cancer treatment.
Product Information
| Product Name | 포토프린(Photofrin®) |
|---|---|
| Manufacturer | Pinnacle Biologics, INC. (USA) |
| Ingredients / Contents | Porfimer sodium 75mg/vial |
| Category / Code | Specialty rare drugs / Antimalignant tumor (412) |
| Compendium | PDR, JP, USP, Vidal, CPS, Matindale |
| Date of permission | 2008. 02. 11 (FDA Approval: 1995. 12.[Esophageal cancer], 1998. 1. Early Lung cancer]) |
| Appearance | a dark red brown, freeze-dried injection powder |
| Effectiveness | Fully closed esophageal cancer or partial closed esophageal cancer that cannot be sufficiently be treated with Nd;YAG laser surgery Decrease in patients’' symptom / complete or partial closure of non-small cell lung cancer (NSCLC) patients in the bronchial tubes and mitigation of symptoms. |
| Dosage | Step 1: Dissolve this medicine in 40mL of the injected physiological saline solution and inject it intravenously with a dose of 2mg/kg for 3-5 minutes slowly. Step 2: Examine the laser light at the cancer area after 40-50 hours after the injection. If there are any remaining tumors, gently remove the necrotic tissue and laser it after 97-120 hours. In clinical trials, necrosis removal using endoscopy is performed two days after initial laser irradiation. Patients can receive a second photodynamic therapy at least 30 days after the initial treatment. This treatment can be received up to three times. (There should be at least 30 days between each procedure.) ※ After diluting this medicine with a solvent, it can be stored up to 24 hours at a temperature of 2-8℃. After dilution, it needs to be used within 3 hours. |
| Package Unit | 1vial/box |
| Official Website | www.photofrin.com |
